Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an announcement.
CSPC Pharmaceutical Group reported a decline in its financial performance for the year 2024, with total revenue dropping by 7.8% and profit attributable to shareholders decreasing by 26.3%. The company completed significant share buy-backs and announced further buy-back plans, reflecting strategic financial management amidst industry challenges and opportunities. The Chinese pharmaceutical industry is experiencing transformative changes driven by policy reforms and innovation incentives, which CSPC is poised to leverage for future growth.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company operating in the pharmaceutical industry. It specializes in the production of finished drugs, bulk products, and functional foods, with a focus on innovative drug development and market expansion in China.
YTD Price Performance: -4.92%
Average Trading Volume: 8,088
Technical Sentiment Signal: Buy
Current Market Cap: $6.95B
For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.